Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Very Bullish +85

Regeneron Stock Jumps 13% to 52-Week High as Sanofi Dupixent Windfall Powers a Blockbuster Third Quarter

Earnings report Guidance raised Licensing agreement AI-generated analysis

πŸ“ˆ Regeneron stock jumped 13% to close at $927.89, reaching a new 52-week high and trading at approximately 20.5 times trailing earnings.

πŸ’° Adjusted earnings per share soared to $20.07, representing a 70% increase year-over-year and significantly exceeding analyst expectations of $16.06.

πŸš€ Revenue grew 36% to $5.12 billion, marking the third consecutive quarter of double-digit growth in both revenue and earnings.

πŸ’Š Dupixent collaboration revenue with Sanofi reached $2.7 billion, up 68%, as Regeneron recorded its full share of partnership profits for the first time.

🀝 The company expanded its alliance with Sanofi to include four next-generation immunology antibodies, triggering a $1 billion upfront payment booked in Q4.

πŸ‘οΈ Newer formulation Eylea HD posted record sales that successfully offset declining revenue from the legacy Eylea eye drug.

πŸ“ˆ Regeneron raised its full-year 2026 guidance for adjusted gross margin on net product sales to approximately 86%.

πŸ”¬ The company continues to advance a pipeline of about 50 clinical programs while managing the transition away from older products.

Bullish Signals
  • Regeneron stock surged 13% to a 52-week high, driven by adjusted earnings per share of $20.07 that beat analyst expectations of $16.06.
  • Revenue increased 36% year-over-year to $5.12 billion, marking the third consecutive quarter of double-digit growth in both revenue and earnings.
  • Collaboration revenue from Sanofi's Dupixent partnership reached $2.7 billion, a 68% increase, as Regeneron recorded its full share of profits for the first time.
  • The company raised its full-year 2026 guidance for adjusted gross margin on net product sales to approximately 86%, up from previous estimates.
  • Record sales of the newer Eylea HD formulation helped offset declining revenue from the legacy Eylea eye drug, stabilizing overall performance.
  • Regeneron expanded its alliance with Sanofi to cover four next-generation immunology antibodies, securing a $1 billion upfront payment booked in Q4.
Full Analysis
Regeneron Pharmaceuticals shares surged 13% to a 52-week high of $927.89 following a blockbuster third-quarter report where adjusted earnings per share hit $20.07, significantly beating the $16.06 consensus. Revenue climbed 36% year-over-year to $5.12 billion, driven primarily by record sales across its key franchises, including Dupixent, Eylea HD, and Libtayo. The company's financial performance was heavily bolstered by its collaboration with Sanofi on the blockbuster drug Dupixent. Collaboration revenue from this partnership reached $2.7 billion, a 68% increase from the prior year, as Regeneron recorded its full share of profits for the first time after repaying development costs in the second quarter. Looking ahead, Regeneron raised its full-year 2026 guidance for adjusted gross margin on net product sales to approximately 86%, up from previous estimates. While legacy eye drug Eylea continues to face headwinds from competition and patient switching, the newer Eylea HD formulation posted record sales that effectively offset this decline. Investors are now focused on the fourth quarter, when Regeneron is expected to book a $1 billion upfront payment from Sanofi related to an expanded alliance covering four next-generation immunology antibodies. The company also maintains a robust pipeline of approximately 50 clinical programs as it navigates the transition away from older products.